Your browser doesn't support javascript.
loading
Anti-A and anti-B haemagglutinin levels in intravenous immunoglobulins: are they on the rise? A comparison of four different analysis methods and six products.
Bellac, C L; Polatti, D; Hottiger, T; Girard, P; Sänger, M; Gilgen, M.
Afiliación
  • Bellac CL; Swissmedic, Swiss Agency for Therapeutic Products, OMCL Biologika, Hallerstrasse 7, CH-3000 Bern 9, Switzerland. Electronic address: caroline.bellac@swissmedic.ch.
  • Polatti D; Swissmedic, Swiss Agency for Therapeutic Products, OMCL Biologika, Hallerstrasse 7, CH-3000 Bern 9, Switzerland.
  • Hottiger T; Swissmedic, Swiss Agency for Therapeutic Products, Market Surveillance, Hallerstrasse 7, CH-3000 Bern 9, Switzerland.
  • Girard P; Swissmedic, Swiss Agency for Therapeutic Products, OMCL Biologika, Hallerstrasse 7, CH-3000 Bern 9, Switzerland.
  • Sänger M; Swissmedic, Swiss Agency for Therapeutic Products, OMCL Biologika, Hallerstrasse 7, CH-3000 Bern 9, Switzerland.
  • Gilgen M; Swissmedic, Swiss Agency for Therapeutic Products, OMCL Biologika, Hallerstrasse 7, CH-3000 Bern 9, Switzerland.
Biologicals ; 42(1): 57-64, 2014 Jan.
Article en En | MEDLINE | ID: mdl-24325871
Recent reports of severe haemolytic reactions upon high dose treatment with new generation intravenous immunoglobulins (IVIGs) prompted us to examine the anti-A and anti-B haemagglutinin content of these therapeutics. We compared four different test methods, namely the indirect and direct haemagglutination test as described in the European Pharmacopoiea (Ph. Eur.) and two commercial gelcard systems with the aim to define the most reliable method for a large-scale comparison of different IVIG products. Absolute titres varied when the same samples were analyzed by the four methods, while the relative ranking of six different IVIG preparations representing different manufacturing classes was identical. New generation IVIGs showed 1-2 titre steps higher anti-A titres than the older products. Haemagglutinin titres of all 48 IVIG batches analyzed were within the current Ph. Eur. specification of ≤1:64 when tested by the official pharmacopoeial method. Based on efficiency, reliability and lower costs, the direct gelcard method could be a valid alternative to the official Ph. Eur. method to serve as a limit test. However, due to the highest intermediate precision, the official Ph. Eur. method seems to be most suitable to compare haemagglutinin titres of different IVIG products.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inmunoglobulinas Intravenosas / Hemaglutininas Límite: Humans Idioma: En Revista: Biologicals Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2014 Tipo del documento: Article Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inmunoglobulinas Intravenosas / Hemaglutininas Límite: Humans Idioma: En Revista: Biologicals Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2014 Tipo del documento: Article Pais de publicación: Reino Unido